Marvel Biosciences Corp. (MRVL.V)

CAD 0.16

(10.34%)

Total Liabilities Summary of Marvel Biosciences Corp.

  • Marvel Biosciences Corp.'s latest annual total liabilities in 2023 was 2.39 Million CAD , up 233.21% from previous year.
  • Marvel Biosciences Corp.'s latest quarterly total liabilities in 2024 Q1 was 2.66 Million CAD , up 11.33% from previous quarter.
  • Marvel Biosciences Corp. reported annual total liabilities of 718 Thousand CAD in 2022, up 538.36% from previous year.
  • Marvel Biosciences Corp. reported annual total liabilities of 112.47 Thousand CAD in 2021, down -36.52% from previous year.
  • Marvel Biosciences Corp. reported quarterly total liabilities of 2.66 Million CAD for 2024 Q1, up 11.33% from previous quarter.
  • Marvel Biosciences Corp. reported quarterly total liabilities of 3.16 Million CAD for 2024 Q2, up 18.85% from previous quarter.

Annual Total Liabilities Chart of Marvel Biosciences Corp. (2023 - 2019)

Historical Annual Total Liabilities of Marvel Biosciences Corp. (2023 - 2019)

Year Total Liabilities Total Liabilities Growth
2023 2.39 Million CAD 233.21%
2022 718 Thousand CAD 538.36%
2021 112.47 Thousand CAD -36.52%
2020 177.18 Thousand CAD 5660.18%
2019 3076.00 CAD 0.0%

Peer Total Liabilities Comparison of Marvel Biosciences Corp.

Name Total Liabilities Total Liabilities Difference
Arch Biopartners Inc. 6.68 Million CAD 64.19%
Covalon Technologies Ltd. 6.1 Million CAD 60.829%
Hemostemix Inc. 7.68 Million CAD 68.868%
Universal Ibogaine Inc. 2.37 Million CAD -0.75%
Kane Biotech Inc. 14.09 Million CAD 83.02%
MedMira Inc. 18.68 Million CAD 87.195%
NervGen Pharma Corp. 15.24 Million CAD 84.307%
XORTX Therapeutics Inc. 1.08 Million CAD -119.679%